Online inquiry

IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2180MR)

This product GTTS-WQ2180MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL15 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000585.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3600
UniProt ID P40933
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2180MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4117MR IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BI-505
GTTS-WQ3771MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ1062MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-621
GTTS-WQ8540MR IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Hu5A8
GTTS-WQ5471MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CDB-1
GTTS-WQ6009MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CNTO 095
GTTS-WQ7145MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FG-3019
GTTS-WQ3975MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BG9924
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW